Search results
Results From The WOW.Com Content Network
Cutis marmorata telangiectatica congenita (CMTC) is a rare congenital vascular disorder that usually manifests in affecting the blood vessels of the skin. The condition was first recognized and described in 1922 by Cato van Lohuizen, [2] a Dutch pediatrician whose name was later adopted in the other common name used to describe the condition – Van Lohuizen syndrome.
This disorder was recognized as a distinct syndrome in 1997 and named macrocephaly-cutis marmorata telangiectasia congenita or M-CMTC. [12] [13] A new name, macrocephaly-capillary malformation, abbreviated M-CM, was recommended in 2007. [14] This new name was chosen to more accurately describe the skin markings associated with this disorder.
Cutis marmorata (from Latin marmor, "marble") is a benign skin condition which, if persistent, occurs in Cornelia de Lange syndrome, trisomy 13 and trisomy 18 syndromes. [1] When a newborn infant is exposed to low environmental temperatures, an evanescent , lacy, reticulated red and/or blue cutaneous vascular pattern appears over most of the ...
Keratosis punctata palmaris et plantaris (Buschke–Fischer–Brauer disease, Davis Colley disease, keratoderma disseminatum palmaris et plantaris, keratosis papulosa, keratoderma punctatum, keratodermia punctata, keratoma hereditarium dissipatum palmare et plantare, palmar and plantar seed dermatoses, palmar keratoses, papulotranslucent ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
This is a list of diseases starting with the letter "M". ... Macrocephaly cutis marmorata telangiectatica; ... Mental retardation arachnodactyly hypotonia telangiectasia;
Research has found that a diet high in ultra-processed foods can raise your risk of developing a slew of health conditions, including type 2 diabetes, heart disease, and some mental health disorders.
A total of 73 children, ages 4 to 14, were originally entered in the trial, which was sponsored and funded by the National Institute of Allergy and Infectious Diseases.